Where capital is flowing and why the tape moves, across funding rounds, M&A, IPOs and market analysis.
Page 4 of 11
Jun 17, 2026InStride’s successful $30 million funding round highlights intensifying demand for pediatric mental health solutions across the United States. The investment signals growing recognition among venture capital and strategic investors of the need for scalable, technology-enabled behavioral health platforms for young patients.
Michael Torres
Jun 9, 2026In an era marked by an industry-wide cash crunch and investor wariness, Parabilis Medicines’ ambitious IPO plan, now upsized to potentially $637 million, stands out. This development represents both a test of market appetite and a signal of ongoing interest in well-positioned biotech innovators, even as broader sector health remains under scrutiny.
Sophia Reynolds
Jun 5, 2026Hydrocephalus treatment is on the cusp of transformation with CereVasc’s minimally invasive eShunt system. The recent $85 million Series C funding round will support pivotal trials and regulatory submissions aimed at providing patients safer and more effective therapeutic options than conventional brain shunts.
Jonathan Blake
Jun 3, 2026This article explores how adopting a comprehensive identity strategy can improve data attribution accuracy, strengthen interoperability among healthcare entities, and ultimately support the effectiveness of value-based care initiatives.
Jonathan Blake
Jun 3, 2026In a significant move for real-world data utilization in drug research, Novellia's platform aims to improve healthcare datasets by sourcing data directly from patients. The recent funding round underscores the growing importance of patient-centric data aggregation in healthcare innovation.
Michael Torres
Jun 3, 2026The fresh capital infusion aims to fuel development and scaling of Ilant Health's approach to treating obesity, a condition with significant global health implications. This investment round reflects growing interest in innovative therapies and digital health platforms targeting metabolic disorders.
Michael Torres
Jun 2, 2026The considerable funding raised by NewLimit underscores growing investor confidence in longevity therapeutics. The company is gearing up for a clinical trial that could pave the way for novel approaches to treating age-related liver diseases.
Dr. Priya Nandakumar
Jun 1, 2026Oral health is increasingly recognized as intrinsic to overall health, especially in pregnant women. This article explores the compelling reasons why obstetricians and gynecologists, public health agencies, and insurance plans should intensify their focus on oral health to reduce pregnancy complications such as pre-eclampsia.
Emily Carter
Jun 1, 2026The glucose monitoring technology initially designed for diabetes care is increasingly being adapted for broader health applications. Signos’ recent $20 million investment round underscores the expanding role of CGM in personalized health, especially focusing on weight management through real-time glucose data and lifestyle recommendations.
Emily Carter
May 31, 2026The health tech sector continues its trajectory of growth with major funding announcements. These investments will support the development of transformative technologies poised to enhance care delivery, improve patient outcomes, and drive healthcare efficiency worldwide.
Emily Carter
May 30, 2026A comprehensive overview of the key executive hires, exits, and workforce reductions during May reveals evolving trends in healthcare management. This shift underscores the dynamic nature of healthcare as it adjusts to new business challenges, innovation demands, and market pressures.
Dr. Alex Morgan
May 28, 2026In a substantial financial commitment, Blackstone Life Sciences will provide up to $1.3 billion in non-dilutive capital to Apogee Therapeutics. This infusion is aimed at advancing clinical development of Apogee’s long-acting antibody therapy with potential applications beyond eczema, including asthma and eosinophilic esophagitis.
Daniel ChoMachine learning, predictive models and computational biology: how AI is changing discovery workflows and probability of success.
Drug development, clinical trials and industry dynamics. What changes timelines, risk and competitive positioning.
Gene therapy, CRISPR, synthetic biology and emerging platforms. Separating what is real from what is hype, and what actually translates.
Digital health, diagnostics and medical devices, and the signals that matter for adoption, reimbursement and outcomes.
FDA actions, approvals, policy shifts and compliance: how the rules change timelines and probability.